Renalytix Plc Share Price (RENX)

I would love to see an update regarding which way they are going on what is the plan. Bio tech companies are not always the best on finance side as they never care about it. They usually closed in labs and only thinking about research.

Update with next steps would be grate.

There is at the bottom a price equiv. to .66 which could be very good news ....

A document named as a prospectus was lodged with NAsdaq on five days ago just prior to the weekend (17th April). Placement 'AD' shares are under ticker RTNXF it comes up in conjuction with our usual ticker.

It is quite a document to wade through I have been reading it for three hours. I have no idea why it was not registered here only in so far as within that document there are several statements which provide that basically only US corporate law namely Delaware law will be adhered to?

Could some others wade through the same document and share their thoughts please as a very heavy read indeed and I am not sure what to make of it at all.

It’s coming soon… pounds not pence! IMHO DYOR

Mikodx - 100% agree that Renx has huge potential. That said - as we are all aware - the company has an FDA approved product (the regulatory bit); a US government approved cost model (the reimbursement bit); and goodness knows how many insurance/healthcare partners signed up who can access the test (the insurance bit). Despite this - there is little evidence that the clinical market is ready to purchase the tests, despite all the validation evidence available. Perhaps the medicare local coverage determination is the final piece in the jigsaw. In its defence the company has achieved a lot in a short time period; however its commercial and financial approach has appeared at odds with its positive healthcare journey. I do not assume a takeover at a decent price is a foregone conclusion; but given the potential there are pharmas/diagnostics who could view this as a bargain - even at multiples of its current valuation. On the subject of dilution - you are correct to note the company currently has c.124m shares in circulation. My estimate was based on the addition of the 26m second close funding placing shares which will be approved at the GM next week - gets you to 150m. Interesting to see if GB Capital take up their option at 30p by close of play tomorrow - if so that adds a further 8m. The convertible bond holder will continue to be paid in shares - currently 3.6m per quarter based on current share price. There are also a significant number of options available to directors, management and employees - exercisable at various values which will effect whether they are taken up - a further 37m in total. Lets hope we get some clarity soon on what's going on. SB